Endocrine system - commissioning policies
Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here.
The CCGs’ position on the implementation of policies affecting patient referral can be found here.
- Alogliptin (Vipidia®) tablets for the treatment of type 2 diabetes
- Dulaglutide (Trulicity®) for the treatment of type 2 diabetes
- FreeStyle Libre for interstitial glucose monitoring in diabetes
- Insulin Degludec 100units/ml (Tresiba®) for Type 1 Diabetes
- Insulin Degludec for Type 2 Diabetes
- Lixisenatide for type 2 diabetes
Please note: Some commissioning policies approved by the previous commissioning organisations have not been reviewed and updated yet. However they are still applicable for the local population and can be accessed here.